MARKET

CSTL

CSTL

Castle Biosciences
NASDAQ
19.77
-0.30
-1.47%
Opening 11:00 04/24 EDT
OPEN
20.05
PREV CLOSE
20.06
HIGH
20.10
LOW
19.75
VOLUME
10.29K
TURNOVER
0
52 WEEK HIGH
26.70
52 WEEK LOW
9.26
MARKET CAP
545.26M
P/E (TTM)
-9.2183
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CSTL last week (0415-0419)?
Weekly Report · 2d ago
Castle Biosciences: Notice of Effectiveness
Press release · 04/17 12:01
Weekly Report: what happened at CSTL last week (0408-0412)?
Weekly Report · 04/15 10:46
Press Release: Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024. The company will release its financial results for the first quarter ended March 31, 2024, after the close of market. Company management will host a conference call and webcast to discuss the financial results on the same day. Castle is a company improving health through innovative tests that guide patient care.
Dow Jones · 04/11 11:04
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
Castle Biosciences recognizes the importance of Esophageal Cancer Awareness Month. The company is supporting key programs and initiatives throughout the month of April. Castle is collaborating with the Esophages Cancer Action Network, Gastro Broadcast podcast and EndoscopyNow to help advance cancer research, prevention and education.
Barchart · 04/10 16:00
Weekly Report: what happened at CSTL last week (0401-0405)?
Weekly Report · 04/08 10:50
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
Castle Biosciences, Inc. Will share new data at the 20th European Association of Dermato-Oncology Congress. Castle will present data on its DecisionDx-Melanoma and Decisiondx-SCC tests. The company says the tests can help guide patient care decisions.
Barchart · 04/04 15:30
Weekly Report: what happened at CSTL last week (0325-0329)?
Weekly Report · 04/01 10:48
More
About CSTL
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Webull offers Castle Biosciences Inc stock information, including NASDAQ: CSTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CSTL stock methods without spending real money on the virtual paper trading platform.